cagrilintide latest news In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintide–semaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results We are all anxiously awaiting

We are all anxiously awaiting more research on the combination of cagrilintide and semaglutide (#ozempic #wegovy) which has been shown in global studies to induce very meaningful #weightloss. This study assessed the efficacy In the REDEFINE 1 phase 3a trial, semaglutide at a dose of 2.4 mg with cagrilintide at a dose of 2.4 mg led to significant body weight reduction in adults without diabetes and Fractyl Health reports one year data suggesting patients may maintain weight loss after stopping GLP 1 drugs. Link in bio. #longevity #glp1 #obesity #weightloss #metabolichealth CagriSema (CagrilintideSemaglutide) in Adults with Overweight or Obesity and Type 2 Diabetes Headlands Research

SKU: 64457385980 · From iglepidom.org